1. MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). (12th June 2019) Authors: Hill, B.T.; Switchenko, J.M.; Martin, P.; Churnetski, M.C.; Sawalha, Y.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.N.; Barta, S.K.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.S.; Mathews, S.; Burkart, M.; Karmali, R.; Ghosh, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. (12th June 2019) Authors: Bond, D.A.; Switchenko, J.; Maddocks, K.; Churnetski, M.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.; Barta, S.; Hill, B.; Salwaha, Y.; Martin, P.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.; Mathews, S.; Burkart, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗